CLINICAL_TRIALS
trial_result
· 2025-11-05
Clinical Trial Update: Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1) [Phase 3]
Summary
Phase 3 CONNEX-1 trial evaluated Iclepertin's impact on cognition and functional capacity in schizophrenia. The study is completed and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2025-11-05